Current management of children with hepatitis C virus mother‐to‐child transmission
2 Prevalence is lower in children, estimated at 0.012% at ages 5–9 years, 0.010% at 10–14 years, and 0.022% at 15–19 years. 2 In 2018, the hepatology group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (JSPGHAN) investigated the epidemiologic features of Japanese c...
Gespeichert in:
| Veröffentlicht in: | Pediatric investigation 2022-01, Vol.64 (1), p.e15053-n/a |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 1 |
| container_start_page | e15053 |
| container_title | Pediatric investigation |
| container_volume | 64 |
| creator | Kondou, Hiroki |
| description | 2 Prevalence is lower in children, estimated at 0.012% at ages 5–9 years, 0.010% at 10–14 years, and 0.022% at 15–19 years. 2 In 2018, the hepatology group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (JSPGHAN) investigated the epidemiologic features of Japanese children born from 1986 to 2015 with HCV infection to clarify natural history and trends over the last three decades. 3 Features of the patients were evaluated in three groups defined by birth year: 1986–1995, 1996–2005, and 2006–2015. 3 Histopathological examination revealed that the classification of fibrosis according to the new Inuyama classification (defined by F0 to F4); F0 33%, F1 58%, F2 9%, and F3-4 0%, indicating that there was no case in which fibrosis progressed to the level of F3 or higher. 3 None of Japanese HCV children developed. 3 Table 1 Putative types of exposure to HCV infection in 348 children 3 Total (n = 348) Group 1 1986–1995 (n = 49) Group 2 1996–2005 (n = 175) Group 3 2006–2015 (n = 124) P values † Maternal, n (%) * 314 (90) 30 (61) 161 (92) 123 (99) |
| doi_str_mv | 10.1111/ped.15053 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2629852126</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629852126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4053-8c03d7f33abf4bccc6f30d25b55a5bef9d0b5629faa98a37378bea958cc2ce4a3</originalsourceid><addsrcrecordid>eNp9kctOwzAQRS0EoqWw4AdQJDawSOv4kThLFMpDqgQLQOwsx3GIqzyKnVB1xyfwjXwJbtNukGAWM6PRmasrXQBOAzgOXE0WKhsHFFK8B4YBIchHEL7uux0j5jMYRgNwZO0cQsgiRg7BANMgomFEhuAl6YxRdetVohZvqlqvTe7JQpeZu3tL3RZeoRai1a22XuJ9aNNZr2raQpnvz6-2cW1De60Rta20tbqpj8FBLkqrTrZzBJ5vpk_JnT97uL1Prma-JM6uzyTEWZRjLNKcpFLKMMcwQzSlVNBU5XEGUxqiOBciZgJHOGKpEjFlUiKpiMAjcNHrLkzz3inbcmdAqrIUtWo6y5F7ZhQFKHTo-S903nSmdu44YjHELA5D-j_FSAxJSGNHXfaUNI21RuV8YXQlzIoHkK8j4S4SvonEsWdbxS6t3HVH7jJwwKQHlrpUq7-V-OP0upf8AdThl3U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2884904659</pqid></control><display><type>article</type><title>Current management of children with hepatitis C virus mother‐to‐child transmission</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Kondou, Hiroki</creator><creatorcontrib>Kondou, Hiroki</creatorcontrib><description>2 Prevalence is lower in children, estimated at 0.012% at ages 5–9 years, 0.010% at 10–14 years, and 0.022% at 15–19 years. 2 In 2018, the hepatology group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (JSPGHAN) investigated the epidemiologic features of Japanese children born from 1986 to 2015 with HCV infection to clarify natural history and trends over the last three decades. 3 Features of the patients were evaluated in three groups defined by birth year: 1986–1995, 1996–2005, and 2006–2015. 3 Histopathological examination revealed that the classification of fibrosis according to the new Inuyama classification (defined by F0 to F4); F0 33%, F1 58%, F2 9%, and F3-4 0%, indicating that there was no case in which fibrosis progressed to the level of F3 or higher. 3 None of Japanese HCV children developed. 3 Table 1 Putative types of exposure to HCV infection in 348 children 3 Total (n = 348) Group 1 1986–1995 (n = 49) Group 2 1996–2005 (n = 175) Group 3 2006–2015 (n = 124) P values † Maternal, n (%) * 314 (90) 30 (61) 161 (92) 123 (99) <0.0001 Horizontal, n (%) 2 (1) 0 2 (1) 0 0.3700 Transfusion, n (%) ** 17 (5) 17 (35) 0 0 <0.0001 Unknown, n (%) *** 15 (4) 2 (4) 12 (7) 1 (1) 0.0398 n, number of patients. *P < 0.0001, Group 1 vs Group 2 and Group 1 vs Group 3; P = 0.0054, Group 2 vs Group 3 by Fisher’s exact test. **P < 0.0001, Group 1 vs Group 2 and Group 1 vs Group 3 by Fisher’s exact test. ***P = 0.0176, Group 2 vs Group 3 by Fisher’s exact test. †Comparison among the three groups by χ2 test. The JSPGHAN published the Japanese version of clinical practice guidelines for the management of children with mother-to-child transmitted HCV infection in 2020, and now the English version is published in this issue. 4 The guideline first states that, in pregnant women who are HCV carriers, elective cesarean delivery does not reduce the rate of mother-to-child transmission, and therefore it is recommended that elective cesarean delivery should not be performed to prevent mother-to-child transmission. 4 However, for HCV carrier mothers with a high viral load, the rate of mother-to-child transmission by mode of delivery in Japan should be explained, and the preferences of mothers and their families should be respected. 4 In addition, as breast-feeding of a child born to an HCV carrier mother does not increase the rate of mother-to-child transmission, it is recommended that formula-feeding to prevent mother-to-child transmission should not be given. 4 Secondly, the introduction of direct-acting antivirals (DAAs) changed the HCV treatment paradigm.</description><identifier>ISSN: 1328-8067</identifier><identifier>ISSN: 2096-3726</identifier><identifier>EISSN: 1442-200X</identifier><identifier>EISSN: 2574-2272</identifier><identifier>DOI: 10.1111/ped.15053</identifier><identifier>PMID: 35175674</identifier><language>eng</language><publisher>Australia: John Wiley & Sons, Inc</publisher><subject>Cesarean section ; Children & youth ; Female ; Hepacivirus ; Hepatitis B virus ; Hepatitis C ; Hepatology ; Humans ; Infant ; Infections ; Infectious Disease Transmission, Vertical - prevention & control ; Pediatrics ; Pregnancy ; Pregnancy Complications, Infectious - drug therapy</subject><ispartof>Pediatric investigation, 2022-01, Vol.64 (1), p.e15053-n/a</ispartof><rights>2022 Japan Pediatric Society</rights><rights>Copyright John Wiley & Sons, Inc. Jan/Dec 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4053-8c03d7f33abf4bccc6f30d25b55a5bef9d0b5629faa98a37378bea958cc2ce4a3</citedby><cites>FETCH-LOGICAL-c4053-8c03d7f33abf4bccc6f30d25b55a5bef9d0b5629faa98a37378bea958cc2ce4a3</cites><orcidid>0000-0002-2461-1303</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fped.15053$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fped.15053$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,864,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35175674$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kondou, Hiroki</creatorcontrib><title>Current management of children with hepatitis C virus mother‐to‐child transmission</title><title>Pediatric investigation</title><addtitle>Pediatr Int</addtitle><description>2 Prevalence is lower in children, estimated at 0.012% at ages 5–9 years, 0.010% at 10–14 years, and 0.022% at 15–19 years. 2 In 2018, the hepatology group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (JSPGHAN) investigated the epidemiologic features of Japanese children born from 1986 to 2015 with HCV infection to clarify natural history and trends over the last three decades. 3 Features of the patients were evaluated in three groups defined by birth year: 1986–1995, 1996–2005, and 2006–2015. 3 Histopathological examination revealed that the classification of fibrosis according to the new Inuyama classification (defined by F0 to F4); F0 33%, F1 58%, F2 9%, and F3-4 0%, indicating that there was no case in which fibrosis progressed to the level of F3 or higher. 3 None of Japanese HCV children developed. 3 Table 1 Putative types of exposure to HCV infection in 348 children 3 Total (n = 348) Group 1 1986–1995 (n = 49) Group 2 1996–2005 (n = 175) Group 3 2006–2015 (n = 124) P values † Maternal, n (%) * 314 (90) 30 (61) 161 (92) 123 (99) <0.0001 Horizontal, n (%) 2 (1) 0 2 (1) 0 0.3700 Transfusion, n (%) ** 17 (5) 17 (35) 0 0 <0.0001 Unknown, n (%) *** 15 (4) 2 (4) 12 (7) 1 (1) 0.0398 n, number of patients. *P < 0.0001, Group 1 vs Group 2 and Group 1 vs Group 3; P = 0.0054, Group 2 vs Group 3 by Fisher’s exact test. **P < 0.0001, Group 1 vs Group 2 and Group 1 vs Group 3 by Fisher’s exact test. ***P = 0.0176, Group 2 vs Group 3 by Fisher’s exact test. †Comparison among the three groups by χ2 test. The JSPGHAN published the Japanese version of clinical practice guidelines for the management of children with mother-to-child transmitted HCV infection in 2020, and now the English version is published in this issue. 4 The guideline first states that, in pregnant women who are HCV carriers, elective cesarean delivery does not reduce the rate of mother-to-child transmission, and therefore it is recommended that elective cesarean delivery should not be performed to prevent mother-to-child transmission. 4 However, for HCV carrier mothers with a high viral load, the rate of mother-to-child transmission by mode of delivery in Japan should be explained, and the preferences of mothers and their families should be respected. 4 In addition, as breast-feeding of a child born to an HCV carrier mother does not increase the rate of mother-to-child transmission, it is recommended that formula-feeding to prevent mother-to-child transmission should not be given. 4 Secondly, the introduction of direct-acting antivirals (DAAs) changed the HCV treatment paradigm.</description><subject>Cesarean section</subject><subject>Children & youth</subject><subject>Female</subject><subject>Hepacivirus</subject><subject>Hepatitis B virus</subject><subject>Hepatitis C</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Infant</subject><subject>Infections</subject><subject>Infectious Disease Transmission, Vertical - prevention & control</subject><subject>Pediatrics</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - drug therapy</subject><issn>1328-8067</issn><issn>2096-3726</issn><issn>1442-200X</issn><issn>2574-2272</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kctOwzAQRS0EoqWw4AdQJDawSOv4kThLFMpDqgQLQOwsx3GIqzyKnVB1xyfwjXwJbtNukGAWM6PRmasrXQBOAzgOXE0WKhsHFFK8B4YBIchHEL7uux0j5jMYRgNwZO0cQsgiRg7BANMgomFEhuAl6YxRdetVohZvqlqvTe7JQpeZu3tL3RZeoRai1a22XuJ9aNNZr2raQpnvz6-2cW1De60Rta20tbqpj8FBLkqrTrZzBJ5vpk_JnT97uL1Prma-JM6uzyTEWZRjLNKcpFLKMMcwQzSlVNBU5XEGUxqiOBciZgJHOGKpEjFlUiKpiMAjcNHrLkzz3inbcmdAqrIUtWo6y5F7ZhQFKHTo-S903nSmdu44YjHELA5D-j_FSAxJSGNHXfaUNI21RuV8YXQlzIoHkK8j4S4SvonEsWdbxS6t3HVH7jJwwKQHlrpUq7-V-OP0upf8AdThl3U</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Kondou, Hiroki</creator><general>John Wiley & Sons, Inc</general><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2461-1303</orcidid></search><sort><creationdate>202201</creationdate><title>Current management of children with hepatitis C virus mother‐to‐child transmission</title><author>Kondou, Hiroki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4053-8c03d7f33abf4bccc6f30d25b55a5bef9d0b5629faa98a37378bea958cc2ce4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cesarean section</topic><topic>Children & youth</topic><topic>Female</topic><topic>Hepacivirus</topic><topic>Hepatitis B virus</topic><topic>Hepatitis C</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Infant</topic><topic>Infections</topic><topic>Infectious Disease Transmission, Vertical - prevention & control</topic><topic>Pediatrics</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kondou, Hiroki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kondou, Hiroki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current management of children with hepatitis C virus mother‐to‐child transmission</atitle><jtitle>Pediatric investigation</jtitle><addtitle>Pediatr Int</addtitle><date>2022-01</date><risdate>2022</risdate><volume>64</volume><issue>1</issue><spage>e15053</spage><epage>n/a</epage><pages>e15053-n/a</pages><issn>1328-8067</issn><issn>2096-3726</issn><eissn>1442-200X</eissn><eissn>2574-2272</eissn><abstract>2 Prevalence is lower in children, estimated at 0.012% at ages 5–9 years, 0.010% at 10–14 years, and 0.022% at 15–19 years. 2 In 2018, the hepatology group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (JSPGHAN) investigated the epidemiologic features of Japanese children born from 1986 to 2015 with HCV infection to clarify natural history and trends over the last three decades. 3 Features of the patients were evaluated in three groups defined by birth year: 1986–1995, 1996–2005, and 2006–2015. 3 Histopathological examination revealed that the classification of fibrosis according to the new Inuyama classification (defined by F0 to F4); F0 33%, F1 58%, F2 9%, and F3-4 0%, indicating that there was no case in which fibrosis progressed to the level of F3 or higher. 3 None of Japanese HCV children developed. 3 Table 1 Putative types of exposure to HCV infection in 348 children 3 Total (n = 348) Group 1 1986–1995 (n = 49) Group 2 1996–2005 (n = 175) Group 3 2006–2015 (n = 124) P values † Maternal, n (%) * 314 (90) 30 (61) 161 (92) 123 (99) <0.0001 Horizontal, n (%) 2 (1) 0 2 (1) 0 0.3700 Transfusion, n (%) ** 17 (5) 17 (35) 0 0 <0.0001 Unknown, n (%) *** 15 (4) 2 (4) 12 (7) 1 (1) 0.0398 n, number of patients. *P < 0.0001, Group 1 vs Group 2 and Group 1 vs Group 3; P = 0.0054, Group 2 vs Group 3 by Fisher’s exact test. **P < 0.0001, Group 1 vs Group 2 and Group 1 vs Group 3 by Fisher’s exact test. ***P = 0.0176, Group 2 vs Group 3 by Fisher’s exact test. †Comparison among the three groups by χ2 test. The JSPGHAN published the Japanese version of clinical practice guidelines for the management of children with mother-to-child transmitted HCV infection in 2020, and now the English version is published in this issue. 4 The guideline first states that, in pregnant women who are HCV carriers, elective cesarean delivery does not reduce the rate of mother-to-child transmission, and therefore it is recommended that elective cesarean delivery should not be performed to prevent mother-to-child transmission. 4 However, for HCV carrier mothers with a high viral load, the rate of mother-to-child transmission by mode of delivery in Japan should be explained, and the preferences of mothers and their families should be respected. 4 In addition, as breast-feeding of a child born to an HCV carrier mother does not increase the rate of mother-to-child transmission, it is recommended that formula-feeding to prevent mother-to-child transmission should not be given. 4 Secondly, the introduction of direct-acting antivirals (DAAs) changed the HCV treatment paradigm.</abstract><cop>Australia</cop><pub>John Wiley & Sons, Inc</pub><pmid>35175674</pmid><doi>10.1111/ped.15053</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-2461-1303</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1328-8067 |
| ispartof | Pediatric investigation, 2022-01, Vol.64 (1), p.e15053-n/a |
| issn | 1328-8067 2096-3726 1442-200X 2574-2272 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2629852126 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central |
| subjects | Cesarean section Children & youth Female Hepacivirus Hepatitis B virus Hepatitis C Hepatology Humans Infant Infections Infectious Disease Transmission, Vertical - prevention & control Pediatrics Pregnancy Pregnancy Complications, Infectious - drug therapy |
| title | Current management of children with hepatitis C virus mother‐to‐child transmission |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T13%3A37%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20management%20of%20children%20with%20hepatitis%20C%20virus%20mother%E2%80%90to%E2%80%90child%20transmission&rft.jtitle=Pediatric%20investigation&rft.au=Kondou,%20Hiroki&rft.date=2022-01&rft.volume=64&rft.issue=1&rft.spage=e15053&rft.epage=n/a&rft.pages=e15053-n/a&rft.issn=1328-8067&rft.eissn=1442-200X&rft_id=info:doi/10.1111/ped.15053&rft_dat=%3Cproquest_cross%3E2629852126%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2884904659&rft_id=info:pmid/35175674&rfr_iscdi=true |